Navigation Links
MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost

In a bid to catalyse malaria and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have assembled a Malaria Box of 400 carefully selected commercially available compounds with antimalarial activity and will provide it to researchers at no cost.

All 400 compounds in the Malaria Box have confirmed activity against the blood-stage of P. falciparum the most deadly of the malaria parasites and were selected by experienced medicinal chemists from an extensive screening of around four million compounds from the chemical libraries of St. Jude Children's Research Hospital, Novartis and GlaxoSmithKline. The Malaria Box includes 200 drug-like compounds as starting points for oral drug discovery as well as 200 probe-like compounds representing the broadest cross-section of chemical diversity for use as biological tools.

"The discovery of novel molecules to feed the pipeline of antimalarial drugs remains a constant challenge," said Tim Wells, CSO of Medicines for Malaria Venture, "and all the more pressing in light of emerging resistance to current therapies. One of the rate-limiting factors for drug discovery is access to the actual active compounds with which to conduct research. With the Malaria Box concept, together with our partner SCYNEXIS, we hope to overcome this hurdle by carefully selecting and making available the most promising molecules to propel malaria drug discovery to the next level."

The scope of the Malaria Box goes beyond the malaria field as the compounds could also be used in research for drugs for other parasitic or neglected diseases. Making the compounds available to the entire neglected-disease community could lead to a better understanding of the similarities and differences between these diseases.

"SCYNEXIS is pleased to participate with MMV in the Malaria Box project as part of our on-going commitment to address the tremendous challenges presented by neglected diseases," said Yves Ribeill, President & CEO of SCYNEXIS, Inc. "SCYNEXIS stands ready to direct its proprietary technologies including its Integrated Parasitology Screening Platform and its HEOS Collaborative Discovery Information Software Platform along with its highly experienced drug discovery teams to find innovative cures for these diseases."

The Malaria Box can be requested free-of-charge from MMV's website. All that is asked in return is that any data gleaned from research on the Box is published, shared and placed into the public domain to continue the virtuous cycle of research.

Contact: Jaya Banerji
Medicines for Malaria Venture

Related biology news :

1. BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS
2. Ancient dry spells offer clues about the future of drought
3. Cheap beads offer alternative solar-heating storage
4. 2 top biological imaging centers offer powerful free online tool to researchers and public
5. Submarine springs offer preview of ocean acidification effects on coral reefs
6. BI-Clinical Offers 100% Coverage of All ACO Quality Measures Released by CMS
7. Targeted antibacterial proteins may offer antibiotic alternative
8. Novel monoclonal antibody offers potential treatment for tumors resistant to VEGF therapy
9. Ultrathin flexible brain implant offers unique look at seizures in NIH-funded research
10. New report offers broad approach to assessing impacts of ecological damage
11. Evolution offers clues to leading cause of death during childbirth
Post Your Comments:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:3/30/2017)... , March 30, 2017 The research ... system for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D ... a new realm of speed and accuracy for use in identification, ... an affordable cost. ... ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
Breaking Biology Technology: